Get 20% off on Global Market Reports until March 31st! Use code FY25SAVE at checkout.
How large is the dravet syndrome market, and what is its growth trajectory?
The dravet syndrome market size has grown strongly in recent years. It will grow from $0.37 billion in 2024 to $0.40 billion in 2025 at a compound annual growth rate (CAGR) of 9.0%. The growth in the historic period can be attributed to the growing prevalence of dravet syndrome, rising diagnosis rates due to better screening, increased funding for epilepsy research, regulatory incentives for orphan drugs, and higher acceptance of cannabis-based treatments.
The dravet syndrome market size is expected to see strong growth in the next few years. It will grow to $0.56 billion in 2029 at a compound annual growth rate (CAGR) of 8.7%. The growth in the forecast period can be attributed to expanding insurance coverage for rare diseases, rising patient advocacy efforts, increasing affordability of genetic testing, stronger government support for rare disease treatment, and growing availability of specialty neurology clinics. Major trends in the forecast period include advancements in gene therapy for seizure control, increasing use of AI for early diagnosis, development of precision medicine for personalized treatment, innovation in drug delivery systems for epilepsy management, and expansion of telehealth for remote patient monitoring.
Get Your Free Sample of The Global Dravet Syndrome Market Report:
https://www.thebusinessresearchcompany.com/sample.aspx?id=21175&type=smp
What are the key forces behind the dravet syndrome market’s growth in recent years?
The rising prevalence of neurological disorders is expected to propel the growth of the dravet syndrome market going forward. Neurological disorders refer to a broad category of conditions that affect the brain, spinal cord, and nervous system, leading to impairments in movement, cognition, sensation, or other bodily functions. Neurological disorders are increasing due to aging populations, lifestyle changes, environmental factors, improved diagnostics, and rising cases of neuroinfections and autoimmune diseases. Dravet syndrome provides valuable insights into neurological disorders by advancing research on genetic mutations, brain excitability, and targeted therapies that could benefit a broader spectrum of neurological conditions. For instance, in April 2022, according to the European Brain Council, a Belgium-based non-profit organization, over 600 neurological diseases and nearly 300 psychiatric conditions afflict millions globally, including 65 million with epilepsy. In Europe, 10.5 million people have dementia, with projections indicating a rise to 18.7 million by 2050. Therefore, the rising prevalence of neurological disorders is driving the growth of the dravet syndrome market.
What are the major segments of the dravet syndrome market?
The dravet syndrome market covered in this report is segmented –
1) By Treatment And Management: Seizure Medications, Ketogenic Diet, Vagus Nerve Stimulation, Other Treatments And Management
2) By Diagnosis: Magnetic Resonance Imaging Testing, Electroencephalography Testing, Sodium Voltage-Gated Channel Alpha Subunit 1 Testing, Other Diagnosis
3) By Route Of Administration: Parenteral Route, Oral Route, Other Routes Of Administration
4) By End-user: Pharmaceutical Companies, Hospitals, Diagnostic Laboratories, Academic And Research Institutes, Other End-users
Subsegments:
1) By Seizure Medications: Anticonvulsants, Benzodiazepines, Levetiracetam, Cannabidiol (CBD) based medications, Topiramate, Lamotrigine
2) By Ketogenic Diet: Standard Ketogenic Diet (SKD), Modified Atkins Diet (MAD), Low Glycemic Index Treatment (LGIT), MCT (Medium Chain Triglyceride) Diet
3) By Vagus Nerve Stimulation: Implantable Vagus Nerve Stimulator (VNS), Non-invasive Vagus Nerve Stimulation (NIVNS), Adjunct Therapy With VNS For Seizure Control
4) By Other Treatments and Management: Physical and Occupational Therapy, Speech Therapy, Epilepsy Surgery, Cognitive Behavioral Therapy (CBT), Genetic Counseling And Support
Order your report now for swift delivery
https://www.thebusinessresearchcompany.com/report/dravet-syndrome-global-market-report
Which companies dominate the dravet syndrome market?
Major companies operating in the dravet syndrome market are Takeda Pharmaceutical Company Limited, Biogen Inc., UCB S.A., Eisai Co. Ltd., Jazz Pharmaceuticals plc, H. Lundbeck A/S, BioMarin Pharmaceutical Inc., PTC Therapeutics Inc., Supernus Pharmaceuticals Inc., Zogenix Inc., Biocodex S.A., Encoded Therapeutics Inc., Marinus Pharmaceuticals Inc., Arvelle Therapeutics GmbH, Stoke Therapeutics Inc., Longboard Pharmaceuticals Inc., Xenon Pharmaceuticals Inc., Aeovian Pharmaceuticals Inc., GW Pharmaceuticals plc, Ovid Therapeutics Inc.
What major trends will shape the dravet syndrome market during the forecast period?
Major companies operating in the dravet syndrome market are focusing on advances in precision medicine, such as RNA-based therapies, to develop targeted treatments that address the underlying genetic mutations associated with Dravet syndrome, aiming to improve efficacy and reduce side effects. RNA-based therapies are treatments that use RNA molecules to modify gene expression or protein production, helping to treat genetic disorders by targeting the underlying causes at the molecular level. For instance, in December 2024, Stoke Therapeutics Inc., a US-based biotechnology company, received U.S. Food and Drug Administration (FDA) approval for zorevunersen for the treatment of dravet syndrome. It is designed to increase the expression of the SCN1A gene, which is often mutated in dravet syndrome patients, thereby addressing the underlying genetic deficiency rather than just managing symptoms. The therapy leverages RNA-based precision medicine to restore proper neuronal function, potentially reducing seizure frequency and improving cognitive outcomes.
What are the key regional dynamics of the dravet syndrome market, and which region leads in market share?
North America was the largest region in the dravet syndrome market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the dravet syndrome market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
What Does The Dravet Syndrome Market Report 2025 Offer?
The dravet syndrome market research report from The Business Research Company offers global market size, growth rate, regional shares, competitor analysis, detailed segments, trends, and opportunities.
Dravet syndrome refers to a rare and severe form of epilepsy that begins in infancy, characterized by prolonged and frequent seizures that are often resistant to treatment. It is used for studying genetic mutations in the SCN1A gene and developing targeted therapies to manage seizure activity and improve patient outcomes.
Purchase the exclusive report now to unlock valuable market insights:
https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=21175
With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead.
Our flagship product, the Global Market Model, is a premier market intelligence platform delivering comprehensive and updated forecasts to support informed decision-making.
Contact Us:
The Business Research Company
Europe: +44 207 1930 708
Asia: +91 88972 63534
Americas: +1 315 623 0293
Email: info@tbrc.info
Follow Us On:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
Twitter: https://twitter.com/tbrc_info
Facebook: https://www.facebook.com/TheBusinessResearchCompany
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Blog: https://blog.tbrc.info/
Healthcare Blog: https://healthcareresearchreports.com/
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model
